Neratinib Maleate

DRUG4 trials

Sponsors

National Cancer Institute (NCI), Korea University Guro Hospital

Conditions

Advanced Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8HER2 Gene MutationLocally Advanced Malignant Solid NeoplasmMalignant Female Reproductive System NeoplasmMalignant Solid NeoplasmMetastatic Cancer

Phase 1

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

SuspendedNCT05372614

National Cancer Institute (NCI)Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm

Start: 2022-10-05End: 2027-01-23Updated: 2026-04-03

Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

RecruitingNCT05564377

National Cancer Institute (NCI)Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 +12

Start: 2023-04-07End: 2030-07-01Target: 2900Updated: 2026-04-03

Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Cancers

CompletedNCT06083662

Korea University Guro HospitalHER2 Gene Mutation, Metastatic Cancer

Start: 2021-06-15End: 2024-12-30Updated: 2025-03-18

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

RecruitingNCT06126276

National Cancer Institute (NCI)Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm +1

Start: 2024-05-07End: 2027-02-20Target: 70Updated: 2026-04-03

Related Papers

Abstract CT071: Phase I trial of trastuzumab deruxtecan in combination with neratinib in solid tumors with HER2 alterations (NCI 10495)

Cancer Research2025-04-251 citations

Phase II study to evaluate safety and efficacy of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors (KCSG AL20-17).

Journal of Clinical Oncology2024-06-01

Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial

The Oncologist2024-05-306 citations

Abstract CT159: Phase I trial of trastuzumab deruxtecan in combination with neratinib in solid tumors with HER2 alterations (NCI 10495)

Cancer Research2024-04-051 citations